Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

Completed · Phase 2

Conditions studied: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder

In brief

This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.

Key facts

Study ID

NCT00139919

Run by

Solvay Pharmaceuticals

Starts

2006-01-01

Expected to finish

2007-10-01

Last updated by the study team

2015-01-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with the current Diagnosis of Schizophrenia, Bipolar Type I Disorder according to DSM-IV TR criteria
• Age 18 to 55
• Body weight 100-250 lbs
• Be sufficiently stable to allow discontinuation of antipsychotic medication

You may not qualify if…

• Acutely psychotic subjects
• Subjects that are acutely manic
• Subjects with a psych diagnosis other than Bipolar Type I Disorder

Where it is running

• Site 1 — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.